Navigation Links
Bacterial Skin and Skin Structure Infections Market: SSSI Pipeline Review, H2 2013 at ReportsnReports.com
Date:1/10/2014

Dallas, Texas (PRWEB) January 10, 2014

Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria. Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review (http://www.reportsnreports.com/reports/271749-skin-and-skin-structure-infections-sssi-caused-by-bacteria-pipeline-review-h2-2013.html), Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • A snapshot of the global therapeutic scenario for Skin And Skin Structure Infections (SSSI) Caused By Bacteria.
  • A review of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Purchase Report @ http://www.reportsnreports.com/purchase.aspx?name=271749.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Inquire for Discount @ http://www.reportsnreports.com/contacts/discount.aspx?name=271749.

List of Tables
Number of Products Under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, H2 2013
Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
GlaxoSmithKline plc, H2 2013
Cubist Pharmaceuticals, Inc., H2 2013
Paratek Pharmaceuticals, Inc., H2 2013
Affinium Pharmaceuticals, Inc., H2 2013
MerLion Pharmaceuticals Pte Ltd, H2 2013
Nabriva Therapeutics AG, H2 2013
Cempra Pharmaceuticals, Inc., H2 2013
Tetraphase Pharmaceuticals Inc., H2 2013
Durata Therapeutics Inc., H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics - Drug Profile Updates
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics - Dormant Products

List of Figures
Number of Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, H2 2013
Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Late Stage Products, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013

Explore more reports from Global Markets Direct Market @ http://www.reportsnreports.com/publisher/global-markets-direct/ and Skincare Market.

About Us
ReportsnReports.com is an online market research reports (http://www.reportsnreports.com/) library of 200,000+ reports and in-depth studies of 5000+ micro markets.

Read the full story at http://www.prweb.com/releases/bacterial-skin-and-skin/structure-infections-sssi/prweb11478629.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Pharmacy Robots Linked to Bacterial Contamination of Drugs
2. Children with juvenile arthritis have higher rates of bacterial infection
3. University of Minnesota startup to treat challenging bacterial infection
4. Fish Pedicure a Recipe for Bacterial Infection, Researchers Warn
5. Zooming in on bacterial weapons in 3-D
6. Killer stainless steel: New process gives icon of cleanliness antibacterial coating
7. Study Ties Kids Allergy Risks to Antibacterials, Preservatives
8. Bacterial Vaginosis Increases Female-to-Male HIV Transmission Risk
9. New mechanism of bacterial pathogenesis discovered
10. AuCoin gets $600,000 to refine new test for deadly bacterial infection melioidosis
11. NIH uses genome sequencing to help quell bacterial outbreak in Clinical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... 2016 , ... Psoriasis: Targets and Therapy has ... corresponding author Professor Luigi Naldi says “The review in Psoriasis: Targets and Therapy ... the onset and the severity of psoriasis, and negatively influences the response to ...
(Date:5/31/2016)... ... May 31, 2016 , ... More than 80 representatives of the ... and the Prevent Cancer Foundation held an event on National Hepatitis Testing Day outside ... of viral hepatitis, the leading cause of liver cancer. , Foundation leaders and the ...
(Date:5/31/2016)... ... ... Twenty years ago it was revolutionary: enabling the people who hear distressing voices to ... this approach has proven transformative, both for people who hear voices and for the ... used around the world, but it still lags in the United States. , Now, ...
(Date:5/31/2016)... , ... May 31, 2016 , ... ... calls back to particular advertising campaigns, to monitor the performance of sales and ... can maximize conversions and revenue. The software allows customers to record, transcribe, route, ...
(Date:5/31/2016)... ... May 31, 2016 , ... Like jewels in a crown, the multiple awards ... is home to Ontario’s leading day spa and one of Canada’s few accredited 5 ... a unique concept to combine spa services with hair and beauty services ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... 30, 2016 According ... Biometrics Market by Technology (Single-factor (Fingerprint, Face, ... Application (Workforce Management), End User (Hospitals, Healthcare ... by MarketsandMarkets, the market is projected to ... USD 1,182.6 Million by 2016, at a ...
(Date:5/30/2016)... - DCGI grants limited approval to market Stempeucel® product for ... Stempeucel® becomes 5th off-the-shelf Stem cell product to be approved by ... Disease (also known as Thromboangiitis Obliterans) is a major unmet medical ... - Prevalence of Buerger,s Disease is estimated to be 1,000,000 in ... the European Community & USA ...
(Date:5/27/2016)... LabStyle Innovations Corp . ( ... today announced that the Company,s Chief Financial Officer, Zvi ... held June 1-2 in New York, NY ... in Los Angeles, CA. ... operational milestones, including the U.S. FDA Clearance and commercial launch ...
Breaking Medicine Technology: